BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 10080835)

  • 1. Evaluation of lymphocytic responses after treatment with Bacillus Calmette-Guerin and interferon-alpha 2b for superficial bladder cancer.
    Gan YH; Mahendran R; James K; Lawrencia C; Esuvaranathan K
    Clin Immunol; 1999 Feb; 90(2):230-7. PubMed ID: 10080835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant bacillus Calmette-Guérin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro.
    Liu W; O'Donnell MA; Chen X; Han R; Luo Y
    Cancer Immunol Immunother; 2009 Oct; 58(10):1647-55. PubMed ID: 19214503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy.
    Luo Y; Chen X; Downs TM; DeWolf WC; O'Donnell MA
    J Immunol; 1999 Feb; 162(4):2399-405. PubMed ID: 9973521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of bacillus-Calmette-Guérin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro.
    Thanhäuser A; Böhle A; Flad HD; Ernst M; Mattern T; Ulmer AJ
    Cancer Immunol Immunother; 1993 Jul; 37(2):105-11. PubMed ID: 8319241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapy.
    Chang SG; Lee SJ; Huh JS; Lee JH
    Oncol Rep; 2001; 8(2):257-61. PubMed ID: 11182036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.
    Zlotta AR; Drowart A; Van Vooren JP; de Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
    J Urol; 1997 Feb; 157(2):492-8. PubMed ID: 8996341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumour immunity of Bacillus Calmette-Guerin and interferon alpha in murine bladder cancer.
    Gan YH; Zhang Y; Khoo HE; Esuvaranathan K
    Eur J Cancer; 1999 Jul; 35(7):1123-9. PubMed ID: 10533458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
    Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S
    Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro generation of bacillus Calmette-Guérin-activated killer cells.
    Brandau S; Böhle A; Thanhäuser A; Ernst M; Mattern T; Ulmer AJ; Flad HD
    Clin Infect Dis; 2000 Sep; 31 Suppl 3():S94-S100. PubMed ID: 11010832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer.
    Pichler R; Fritz J; Zavadil C; Schäfer G; Culig Z; Brunner A
    Oncotarget; 2016 Jun; 7(26):39916-39930. PubMed ID: 27221038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacillus Calmette-Guérin plus intravesical interferon alpha-2b in patients with superficial bladder cancer.
    Stricker P; Pryor K; Nicholson T; Goldstein D; Golovsky D; Ferguson R; Nash P; Ehsman S; Rumma J; Mammen G; Penny R
    Urology; 1996 Dec; 48(6):957-61; discussion 961-2. PubMed ID: 8973689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the immunologic mechanism of intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors: distribution and function of immune cells.
    Chung JY; Lee ES; Lee WJ; Kim HH; Min KJ; Lee C
    J Korean Med Sci; 1993 Apr; 8(2):135-44. PubMed ID: 8397930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin.
    De Boer EC; De Jong WH; Van Der Meijden AP; Steerenberg PA; Witjes JA; Vegt PD; Debruyne FM; Ruitenberg EJ
    Cancer Immunol Immunother; 1991; 33(6):411-6. PubMed ID: 1878894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissecting the immunobiological effects of Bacillus Calmette-Guérin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon.
    Böhle A; Thanhäuser A; Ulmer AJ; Ernst M; Flad HD; Jocham D
    J Urol; 1993 Dec; 150(6):1932-7. PubMed ID: 8230540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer.
    De Boer EC; De Jong WH; Steerenberg PA; Aarden LA; Tetteroo E; De Groot ER; Van der Meijden AP; Vegt PD; Debruyne FM; Ruitenberg EJ
    Cancer Immunol Immunother; 1992; 34(5):306-12. PubMed ID: 1540977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells.
    Brandau S; Suttmann H; Riemensberger J; Seitzer U; Arnold J; Durek C; Jocham D; Flad HD; Böhle A
    Clin Cancer Res; 2000 Sep; 6(9):3729-38. PubMed ID: 10999767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immunotherapy.
    Jackson AM; Alexandroff AB; Kelly RW; Skibinska A; Esuvaranathan K; Prescott S; Chisholm GD; James K
    Clin Exp Immunol; 1995 Mar; 99(3):369-75. PubMed ID: 7882559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
    Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
    Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
    de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
    J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Predictive Value of Urinary Cytokine Profile Induced During Intravesical Bacillus Calmette-Guérin Instillations for Bladder Cancer.
    Rigaud J; Leger A; Devilder MC; Bouchot O; Bonneville M; Scotet E
    Clin Genitourin Cancer; 2015 Aug; 13(4):e209-e215. PubMed ID: 25735197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.